Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood

• Publication date

  2011-11-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2011-04-348540PMID 21849486PMCID PMC3208293
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CARs on track in the clinic.

  2011cited by this paper
• Modern therapy of acute lymphoblastic leukemia.

  2011cited by this paper
• Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

  2010cited by this paper
• Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

  2010cited by this paper
• Adoptive T cell therapy of cancer.

  2010cited by this paper
• Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic.

  2010cited by this paper
• Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.

  2010cited by this paper
• Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells.

  2010cited by this paper
• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

  2010cited by this paper
• Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.

  2010cited by this paper
• Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.

  2009cited by this paper
• Fludarabine Modulates Immune Response and Extends In Vivo Survival of Adoptively Transferred CD8 T Cells in Patients with Metastatic Melanoma

  2009cited by this paper
• The promise and potential pitfalls of chimeric antigen receptors.

  2009cited by this paper
• Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

  2009cited by this paper
• T-cell engineering for cancer immunotherapy.

  2009cited by this paper
• Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".

  2009cited by this paper
• Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

  2009cited by this paper
• The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B‐cell lymphoma

  2008cited by this paper
• Chronic lymphocytic leukaemia.

  2008cited by this paper
• Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

  2008cited by this paper
• Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

  2008cited by this paper
• Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

  2008cited by this paper
• Optimizing Adoptive Polyclonal T Cell Immunotherapy of Lymphomas, Using a Chimeric T Cell Receptor Possessing CD28 and CD137 Costimulatory Domains

  2007cited by this paper
• Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.

  2007cited by this paper
• Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts

  2007cited by this paper
• CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

  2006cited by this paper
• T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.

  2006cited by this paper
• Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

  2006cited by this paper
• A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

  2006cited by this paper
• Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

  2005cited by this paper
• Are we nearly there yet

  2005cited by this paper
• In Vitro Engagement of CD3 and CD28 Corrects T Cell Defects in Chronic Lymphocytic Leukemia1

  2005cited by this paper
• Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15

  2003cited by this paper
• Targeting tumours with genetically enhanced T lymphocytes

  2003cited by this paper
• Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction.

  2003cited by this paper
• A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.

  2003cited by this paper
• T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.

  2003cited by this paper
• Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

  2002cited by this paper
• Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells

  2000cited by this paper
• Impairments in immune cell function in B cell chronic lymphocytic leukemia.

  1998cited by this paper
• Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.

  1998cited by this paper
• Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen.

  1996cited by this paper
• CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.

  1995cited by this paper
• Immunophenotyping of low‐grade B‐cell lymphoma in blood and bone marrow: poor correlation between immunophenotype and cytological/histological classification

  1993cited by this paper
• Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.

  1993cited by this paper
• Immunophenotype of acute lymphoblastic leukemia cells: the experience of the Italian Cooperative Group (Gimema).

  1993cited by this paper
• Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins.

  1988cited by this paper
• CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail

  1988cited by this paper
• Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

  1982cited by this paper
• Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred

  year unknowncited by this paper

• Engineering a fifth-generation CAR T cells to overcome PD-L1-mediated immunosuppression in lung cancer.

  2026cites this paper
• Double refractory chronic lymphocytic leukemia: clinical scenarios and therapeutic strategies.

  2026cites this paper
• Research progress on the influence of tumor microenvironment on immunotherapy for pancreatic ductal adenocarcinoma

  2026cites this paper
• Put the CAR-T before the HRS: Advances in Anti-CD30 Immunotherapy Targeting Hodgkin/Reed-Sternberg Cells in Classical Hodgkin Lymphoma.

  2026cites this paper
• Unsupervised Machine Learning‐Based Process Analytical Tools for Near Real‐Time Cell Morphology Analysis During CAR‐T Cell Manufacturing

  2025cites this paper
• Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia

  2025cites this paper
• Tracing the development of CAR-T cell design: from concept to next-generation platforms

  2025cites this paper
• Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment

  2025cites this paper
• Adoptive T Cell Therapy Targeting MAGE-A4

  2025cites this paper
• Efficient expansion of tumor-infiltrating lymphocytes from gynecologic cancer.

  2025cites this paper
• CAR-T cell therapy for cancer: current challenges and future directions

  2025cites this paper
• GD2TIF cells as a platform for single-dose and long-term delivery of biologics

  2025cites this paper
• A phase I trial of combination CAR-NK92MI immunotherapy by dual targeting MUC-1 and PD-L1 for patients with relapsed or refractory solid tumors: focus on non-small cell lung cancer

  2025cites this paper
• From concept to cure: Molecular mechanisms, clinical triumphs, and future horizons of chimeric antigen receptor T-cell therapy

  2025cites this paper
• Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines

  2025cites this paper
• Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies

  2025cites this paper
• Emerging cell therapies in the vasculitis field.

  2025cites this paper
• Diverse potential of chimeric antigen receptor‐engineered cell therapy: Beyond cancer

  2025cites this paper
• Elevated CD10− neutrophils correlate with non-response and poor prognosis of CD19 CAR T-cell therapy for B-cell acute lymphoblastic leukemia

  2025cites this paper
• T cell exhaustion in pediatric B-ALL: current knowledge and future perspectives

  2025cites this paper
• CAR-T cell therapy: A therapeutic strategy for cancer treatment.

  2025cites this paper
• Innate Immune Cells in Chimeric Antigen Receptor Therapy.

  2025cites this paper
• Recent advances and challenges of cellular immunotherapies in lung cancer treatment

  2025cites this paper
• Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure

  2025cites this paper
• NanoLuc/h-coelenterazine: an efficient pair for bioluminescence imaging in vivo and in vivo

  2025cites this paper
• CD371-Targeted CAR T cells Secreting Interleukin-18 Exhibit Robust Expansion and Clear Refractory Acute Myeloid Leukemia.

  2025cites this paper
• Retroviral Vector Technology for Gene Therapy: History, Current Landscape, and Future Prospects.

  2025cites this paper
• Leveraging T cells for cancer immunotherapy

  2025cites this paper
• CAR T-cell therapy in systemic sclerosis: the next frontier in immune modulation.

  2025cites this paper
• The race between 4-1BB- and CD28-based CD19 CAR-T products in the therapy of B-cell malignancies

  2025cites this paper
• Research progress of T cells in cholangiocarcinoma

  2025cites this paper
• Cord blood-derived iNK T cells as a platform for allogeneic CAR T cell therapy

  2025cites this paper
• Development of an innovative approach for early diagnosis of cervical cancer using TCR-like antibodies targeting HPV18 E6 and E7 peptides

  2025cites this paper
• A Quantitative Approach to Potency Testing for Chimeric Antigen Receptor-Encoding Lentiviral Vectors and Autologous CAR-T Cell Products, Using Flow Cytometry

  2025cites this paper
• Overcoming chimeric antigen receptor-T (CAR-T) resistance with checkpoint inhibitors: Existing methods, challenges, clinical success, and future prospects: A comprehensive review.

  2025cites this paper
• Gene Therapy Then and Now: A Look Back at Changes in the Field Over the Past 25 Years.

  2025cites this paper
• CAR T Cell Therapy for Glioblastoma: A Review of the First Decade of Clinical Trials.

  2025cites this paper
• Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma

  2025cites this paper
• Advances in viral vector-based delivery systems for gene therapy: a comprehensive review

  2025cites this paper
• Can autoimmune disease be cured by deep CD19+ cell depletion?

  2025cites this paper
• Tracking cellular therapies to optimize homing against liver metastases

  2025cites this paper
• Quantitative Insights into CAR-T Cell Therapy: The Interplay of Dose, Dosing Regimen, Proliferation and Tumour Elimination

  2025cites this paper
• A Meta-analysis on Effects of Chimeric Antigen Receptor T-cell Therapy in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

  2025cites this paper
• Cellular Kinetics and Biodistribution of Adoptive T Cell Therapies: from Biological Principles to Effects on Patient Outcomes

  2025cites this paper
• Challenges in the preclinical design and assessment of CAR-T cells

  2025cites this paper
• CAR-T Cell Therapy for Prostate Cancer: Current Advances and Future Perspectives

  2025cites this paper
• Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy.

  2025cites this paper
• TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity

  2024cites this paper
• 100 years of the Warburg effect: A cancer metabolism endeavor.

  2024cites this paper
• Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy

  2024cites this paper
• Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers

  2024cites this paper
• Strategies for Improving CAR T Cell Persistence in Solid Tumors

  2024cites this paper
• CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient’s age, and tumor types

  2024cites this paper
• CAR-T Cells – Main Steps for Obtaining a Proper “Live Drug” Adoptive Therapy

  2024cites this paper
• Stem‐like T cells in cancer and autoimmunity

  2024cites this paper
• Chimeric Antigen Receptor T-Cells (CAR T-Cells): An Engineered Targeted Therapy for Treatment of Cancer

  2024cites this paper
• Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives

  2024cites this paper
• Engineered cell membrane-coated nanoparticles based cancer therapy: A robust weapon against the lethal and challenging hepatocellular carcinoma.

  2024cites this paper
• Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy

  2024cites this paper
• iPS cell therapy 2.0: Preparing for next‐generation regenerative medicine

  2024cites this paper
• The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?

  2024cites this paper
• Non-viral delivery of RNA for therapeutic T cell engineering.

  2024cites this paper
• Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas

  2024cites this paper
• BATF-mediated regulation of exhausted CD8+ T-cell responses and potential implications for chimeric antigen receptor-T therapy.

  2024cites this paper
• Immunometabolic adaptation of CD19-targeted CAR T cells in the central nervous system microenvironment of patients promotes memory development.

  2024cites this paper
• Expanding CAR-T cell immunotherapy horizons through microfluidics.

  2024cites this paper
• Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications

  2024cites this paper
• Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model

  2024cites this paper
• Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias

  2024cites this paper
• CAR T Cell Nanosymbionts: Revealing the Boundless Potential of a New Dyad

  2024cites this paper
• CAR assembly line: Taking CAR T-cell manufacturing to the next level.

  2024cites this paper
• CAR-T cell therapy for breast cancer: Current status and future perspective.

  2024cites this paper
• Chimeric antigen receptor T-cell therapy in autoimmune diseases

  2024cites this paper
• Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells

  2024cites this paper
• Relapsed/refractory CLL: the role of allo-SCT, CAR-T, and T-cell engagers.

  2024cites this paper
• Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma.

  2024cites this paper
• Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies.

  2024cites this paper
• Targeting cardiac fibrosis with Chimeric Antigen Receptor-Engineered Cells

  2024cites this paper
• Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system

  2024cites this paper
• CHIMERIC ANTIGEN RECEPTOR T CELLS: PAST, PRESENT, AND FUTURE

  2024cites this paper
• Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis

  2024cites this paper
• Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma

  2024cites this paper
• Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia

  2024cites this paper
• A Biomaterial Platform for T Cell-Specific Gene Delivery.

  2024cites this paper
• The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer

  2024cites this paper
• Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope?

  2024cites this paper
• CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy

  2024cites this paper
• A quality-by-design approach to improve process understanding and optimise the production and quality of CAR-T cells in automated stirred-tank bioreactors

  2024cites this paper
• Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

  2024cites this paper
• Principles and therapeutic applications of adaptive immunity.

  2024cites this paper
• Targeted gene delivery systems for T-cell engineering

  2024cites this paper
• The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation

  2024cites this paper
• Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells

  2024cites this paper
• Chimeric antigen receptor T cell therapy for autoimmune disease

  2024cites this paper
• Advances in CRISPR-Cas systems for blood cancer.

  2024cites this paper
• Engineering CAR-T therapies for autoimmune disease and beyond.

  2024cites this paper
• Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy

  2024cites this paper
• Chimeric HLA antibody receptor T cell therapy for humoral transplant rejection.

  2024cites this paper
• Gene Targets of CAR-T Cell Therapy for Glioblastoma

  2023cites this paper
• Long-term outcomes following CAR T cell therapy: what we know so far

  2023cites this paper